[{"Assets_0_Q2_USD":11225600000.0,"CommonStockSharesOutstanding_0_Q2_shares":137600000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":254700000.0,"NetIncomeLoss_1_Q2_USD":36200000.0,"NetIncomeLoss_2_Q2_USD":117000000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":138700000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":140000000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":138100000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":139500000.0,"StockholdersEquity_0_Q2_USD":5897100000.0,"EarningsPerShareBasic_1_Q2_USD":0.26,"EarningsPerShareBasic_2_Q2_USD":0.84,"EarningsPerShareDiluted_1_Q2_USD":0.26,"EarningsPerShareDiluted_2_Q2_USD":0.84,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":1186400000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":2403400000.0,"Ticker":"PRGO","CIK":"1585364","name":"PERRIGO CO PLC","OfficialName":"Perrigo Company plc Ordinary Shares","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"4754722726.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"nan","filed":"20180809"}]